PRAX Praxis Precision Medicines, Inc.

NASDAQ
$366.81

Praxis Precision Medicines, Inc. (PRAX) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $3.65 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.7% since its last earnings release on August 6, 2026.

Praxis Precision Medicines Beat Consensus Estimates
Thursday, August 6, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 8:00 AM ET
Earnings Whisper
-
vs ($3.65)
Rev est $8.21M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $370.34

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.

Sector

Healthcare

Industry

Biotechnology